Quotient Wealth Partners LLC Makes New $212,000 Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• Quotient Wealth Partners LLC invested approximately $212,000 in IDEXX Laboratories, acquiring 395 shares during the second quarter.
• Analysts have generally positive outlooks on IDEXX Laboratories, with several firms raising their price targets, including a jump from $550.00 to $675.00 by JPMorgan Chase & Co.
• IDEXX reported $3.63 earnings per share for its latest quarter, exceeding analyst expectations of $3.28, along with a 24.41% net margin.

Quotient Wealth Partners LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 395 shares of the company's stock, valued at approximately $212,000.

A number of other institutional investors also recently bought and sold shares of the company. Stratos Wealth Partners LTD. raised its stake in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company's stock worth $564,000 after purchasing an additional 18 shares during the period. Nordea Investment Management AB raised its stake in IDEXX Laboratories by 4.7% during the second quarter. Nordea Investment Management AB now owns 8,057 shares of the company's stock worth $4,298,000 after purchasing an additional 361 shares during the period. Aware Super Pty Ltd as trustee of Aware Super raised its stake in IDEXX Laboratories by 41.8% during the second quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 62,291 shares of the company's stock worth $33,409,000 after purchasing an additional 18,375 shares during the period. Alta Capital Management LLC raised its stake in IDEXX Laboratories by 6.0% during the second quarter. Alta Capital Management LLC now owns 22,143 shares of the company's stock worth $11,876,000 after purchasing an additional 1,253 shares during the period. Finally, Mutual Advisors LLC purchased a new position in IDEXX Laboratories during the second quarter worth about $244,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on IDXX. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. Weiss Ratings reiterated a "buy (b-)" rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. BTIG Research lifted their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Finally, Piper Sandler reiterated a "neutral" rating and set a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $656.50.

IDEXX Laboratories Trading Down 0.3%

Shares of IDXX stock opened at $635.40 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market capitalization of $50.83 billion, a P/E ratio of 52.91, a price-to-earnings-growth ratio of 4.11 and a beta of 1.58. The company has a 50 day moving average price of $639.99 and a 200 day moving average price of $551.18. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares in the company, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares of the company's stock, valued at $4,011,249.60. This trade represents a 46.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.